GlassScriptPhysician profile
John A Robertson
NPI 1821059478
$4,714.82
in general payments reported to CMS, 2019-2025
27 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $50.63 · 2021: $14.16 · 2022: $491 · 2023: $1,220 · 2024: $1,257 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.73 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $793.91 | 2019-2025 | |
| Glaxosmithkline, LLC. | $752.48 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $580.06 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $474.65 | 2022-2025 | Ubrelvy, Qulipta, Vraylar |
| Astellas Pharma US INC | $293.59 | 2019-2024 | Veozah, Myrbetriq |
| Novo Nordisk INC | $234.19 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $223.00 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Amgen INC. | $202.30 | 2019-2024 | Repatha, Otezla, Prolia |
| Sumitomo Pharma America, INC. | $165.74 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $163.83 | 2023-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Shield Therapeutics INC | $124.81 | 2025 | |
| Merck Sharp & Dohme LLC | $113.97 | 2021-2024 | Verquvo, Steglatro, Belsomra |
| Dexcom, INC. | $109.16 | 2022-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $84.89 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $70.21 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.66 | 2019-2023 | Jardiance |
| Xeris Pharmaceuticals, INC. | $41.66 | 2024 | Gvoke Hypopen |
| Exact Sciences Corporation | $36.28 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $33.99 | 2019 | |
| Pulmonx Corporation | $25.60 | 2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Teva Pharmaceuticals USA, INC. | $25.40 | 2019 | |
| Janssen Pharmaceuticals, INC | $23.87 | 2019 | |
| Dynavax Technologies Corporation | $22.94 | 2024 | Heplisav-B |
| Gilead Sciences, INC. | $22.40 | 2025 | |
| Axsome Therapeutics, INC. | $19.06 | 2025 | Symbravo |
| Viatris Specialty LLC | $18.90 | 2025 | Yupelri |
| Shire North American Group INC | $13.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.